THE EFFECT OF CIPROFLOXACIN ON THEOPHYLLINE PHARMACOKINETICS IN HEALTHY-SUBJECTS

被引:53
|
作者
BATTY, KT
DAVIS, TME
ILETT, KF
DUSCI, LJ
LANGTON, SR
机构
[1] UNIV WESTERN AUSTRALIA,FREMANTLE HOSP,DEPT MED,FREMANTLE,WA 6160,AUSTRALIA
[2] UNIV WESTERN AUSTRALIA,STATE HLTH LAB SERV,COMBINED UNIT CLIN PHARMACOL & TOXICOL,NEDLANDS,WA 6009,AUSTRALIA
[3] FREMANTLE HOSP,DEPT BIOCHEM,FREMANTLE,WA 6160,AUSTRALIA
关键词
CIPROFLOXACIN; THEOPHYLLINE; DRUG INTERACTIONS; HUMANS; PHARMACOKINETICS;
D O I
10.1111/j.1365-2125.1995.tb04453.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 The mechanism of the interaction between ciprofloxacin and theophylline was investigated in nine healthy subjects, 2 Subjects were given a single oral dose of theophylline (3.4 mg kg(-1)), before and after 60 h of ciprofloxacin therapy at a dose of 500 mg twice daily. 3 Ciprofloxacin reduced the oral clearance of theophylline by 19% (-7.73 +/- 6.42 ml kg(-1) h(-1) (95% confidence limits -12.66, -2.79)). Some subjects (group A, n = 4) showed little decrease in clearance (mean 4.4%; -1.6 +/- 0.7 ml kg(-1) h(-1) (-26, -0.5)), whereas others (group B, n = 5) showed a marked decrease (mean 30%; -12.7 +/- 3.7 mi kg(-1) h(-1) (-17.2, -8.1)). 4 Comparing groups A and B, the decrease in oral clearance of theophylline in group B could not be ascribed to differences in the AUC of ciprofloxacin. Group A subjects showed only slight inhibition of l-demethylation (-12.8 +/- 5.5% (-21.5, -4.0)), while group B subjects showed a significantly greater inhibition of l-demethylation (-49.9 +/- 9.8% (-62.1, -37.7)), 3-demethylation (-44.8 +/- 8.6% (-55.4, -34.1)) and 8-hydroxylation (-27.0 +/- 3.7% (-31.6, -22.4)), 5 The results suggest that inter-individual variability in the inhibition of theophylline metabolism by ciprofloxacin can be attributed to inter-individual differences in the level of CYP1A2 expression and/or in the degree of inhibition of hepatic CYP1A2 and CYP3A4. 6 The interaction between ciprofloxacin and theophylline can be clinically significant. However, uniform decrease in the theophylline dose is not warranted because there is a negligible change in theophylline clearance when ciprofloxacin is coadministered in a substantial proportion of patients.
引用
下载
收藏
页码:305 / 311
页数:7
相关论文
共 50 条
  • [1] EFFECT OF SUSTAINED-RELEASE ON THE PHARMACOKINETICS OF THEOPHYLLINE IN HEALTHY-SUBJECTS
    BIALER, M
    SALAME, K
    RAZ, I
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1985, 23 (12) : 662 - 667
  • [2] EFFECT OF MORICIZINE ON THE PHARMACOKINETICS OF SINGLE-DOSE THEOPHYLLINE IN HEALTHY-SUBJECTS
    PIENIASZEK, HJ
    DAVIDSON, AF
    BENEDEK, IH
    THERAPEUTIC DRUG MONITORING, 1993, 15 (03) : 199 - 203
  • [3] PHARMACOKINETICS OF A SUSTAINED-RELEASE THEOPHYLLINE PREPARATION IN HEALTHY-SUBJECTS
    GOTO, M
    NAKAMOTO, Y
    SUGIYAMA, M
    YAMASHINA, H
    JOURNAL OF PHARMACOBIO-DYNAMICS, 1983, 6 (04): : 225 - 231
  • [4] EFFECTS OF ROXATIDINE ACETATE HYDROCHLORIDE AND CIMETIDINE ON THE PHARMACOKINETICS OF THEOPHYLLINE IN HEALTHY-SUBJECTS
    YOSHIMURA, N
    TAKEUCHI, H
    OGATA, H
    ISHIOKA, T
    AOI, R
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1989, 27 (06) : 308 - 312
  • [5] DIURNAL-VARIATION IN THE PHARMACOKINETICS OF INTRAVENOUS THEOPHYLLINE AND ETOPHYLLINE IN HEALTHY-SUBJECTS
    CHAUHAN, BL
    DOSHI, BS
    KULKARNI, RD
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 30 (05) : 635 - 636
  • [6] EFFECT OF THE ADDITION OF CIPROFLOXACIN ON THEOPHYLLINE PHARMACOKINETICS IN SUBJECTS INHIBITED BY CIMETIDINE
    DAVIS, RL
    QUENZER, RW
    KELLY, HW
    POWELL, JR
    ANNALS OF PHARMACOTHERAPY, 1992, 26 (01) : 11 - 13
  • [7] PHARMACOKINETICS OF MECILLINAM IN HEALTHY-SUBJECTS
    GAMBERTOGLIO, JG
    BARRIERE, SL
    LIN, ET
    CONTE, JE
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1980, 18 (06) : 952 - 956
  • [8] PHARMACOKINETICS OF AZLOCILLIN IN HEALTHY-SUBJECTS
    LEROY, A
    HUMBERT, G
    FILLASTRE, JP
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1981, : 49 - 54
  • [9] PHARMACOKINETICS OF RILMENIDINE IN HEALTHY-SUBJECTS
    GENISSEL, P
    BROMET, N
    FOURTILLAN, JB
    MIGNOT, A
    ALBIN, H
    AMERICAN JOURNAL OF CARDIOLOGY, 1988, 61 (07): : D47 - D53
  • [10] PHARMACOKINETICS OF NADOLOL IN HEALTHY-SUBJECTS
    SCHAFERKORTING, M
    BACH, N
    KNAUF, H
    MUTSCHLER, E
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 26 (01) : 125 - 127